Ahmed Yousef
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ahmed Yousef has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Ahmed Abd El Latif
Beni-Suef University, Banī Suwayf, Egypt
1 shared publicationAhmed Abo Zamel
Kasr Alainy Hospital, Cairo University, Cairo, Egypt
1 shared publicationAhmed G. Mohamed
Beni-Suef University, Banī Suwayf, Egypt
1 shared publication- Ahmed G. Mohamed
Department of Urology, Beni-Suef University Faculty of Medicine, Beni-Suef, Egypt
1 shared publication - Al Shaimaa Ibrahim Rabie
Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62521, Egypt
1 shared publication Alexander Kugler
Klinikum Fichtelgebirge, Marktredwitz, Germany
1 shared publication
Latest Publications
- Open Access
- 26 September 2025
- Published by Springer Nature in African Journal of Urology
- Vol. 31 (1) , 1-6
Fosfomycin, trimethoprim/sulfamethoxazole, or ciprofloxacin: which is better for infection prophylaxis with transrectal prostatic biopsy? Multicenter study
Background: Antibiotic prophylaxis is necessary to avoid infectious complications following transrectal ultrasound-guided prostate biopsy (TRUSPB). Till now, there is no consensus or international agreement for the optimal type of antibiotics, particularly after the recommendation against using fluoroquinolones as antibiotic prophylaxis due to their toxicity profile and the increasing bacterial resistance to them. Aim of the work: This study aimed to retrospectively compare the efficacy of ciprofloxacin, trimethoprim/sulfamethoxazole, or fosfomycin as perioperative prophylaxis in patients undergoing TRUSBP. Patients and methods: We retrospectively analyzed 502 patients who underwent TRUSPB in 2 urological facilities in Egypt and Germany between June 2020 and July 2023 and received either ciprofloxacin (n: 121), trimethoprim/sulfamethoxazole (n: 109), or fosfomycin (n: 272) as antibiotic prophylaxis. Infection rate and site and sepsis rates were assessed within 1 month after the procedure. The causative organism, management protocol, and antibiotics used in management were also studied. Results: Infections developed among 3.3% of patients who received fosfomycin, 2.8% who received trimethoprim/sulfamethoxazole, and 0.8% who received ciprofloxacin. The results showed no statistically significant difference among the 3 arms. In Egypt and Germany E. coli was the most common causative Organism. Although there were different management strategies between Egypt and Germany, there was no fatal complication or intensive care admission in the three groups. Conclusions: Fosfomycin, ciprofloxacin, and trimethoprim/sulfamethoxazole effectively prevent post-transrectal prostate biopsy infections. Further research is needed to evaluate the efficacy and safety of different types of antibiotics in different populations in which regional variations in pathogen prevalence and resistance patterns should be considered.
- 26 September 2025
- Published by Springer Nature in African Journal of Urology
- Vol. 31 (1) , 1-6
Open AccessFosfomycin, trimethoprim/sulfamethoxazole, or ciprofloxacin: which is better for infection prophylaxis with transrectal prostatic biopsy? Multicenter study
Background: Antibiotic prophylaxis is necessary to avoid infectious complications following transrectal ultrasound-guided prostate biopsy (TRUSPB). Till now, there is no consensus or international agreement for the optimal type of antibiotics, particularly after the recommendation against using fluoroquinolones as antibiotic prophylaxis due to their toxicity profile and the increasing bacterial resistance to them. Aim of the work: This study aimed to retrospectively compare the efficacy of ciprofloxacin, trimethoprim/sulfamethoxazole, or fosfomycin as perioperative prophylaxis in patients undergoing TRUSBP. Patients and methods: We retrospectively analyzed 502 patients who underwent TRUSPB in 2 urological facilities in Egypt and Germany between June 2020 and July 2023 and received either ciprofloxacin (n: 121), trimethoprim/sulfamethoxazole (n: 109), or fosfomycin (n: 272) as antibiotic prophylaxis. Infection rate and site and sepsis rates were assessed within 1 month after the procedure. The causative organism, management protocol, and antibiotics used in management were also studied. Results: Infections developed among 3.3% of patients who received fosfomycin, 2.8% who received trimethoprim/sulfamethoxazole, and 0.8% who received ciprofloxacin. The results showed no statistically significant difference among the 3 arms. In Egypt and Germany E. coli was the most common causative Organism. Although there were different management strategies between Egypt and Germany, there was no fatal complication or intensive care admission in the three groups. Conclusions: Fosfomycin, ciprofloxacin, and trimethoprim/sulfamethoxazole effectively prevent post-transrectal prostate biopsy infections. Further research is needed to evaluate the efficacy and safety of different types of antibiotics in different populations in which regional variations in pathogen prevalence and resistance patterns should be considered.
- Open Access
- 21 January 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (3) , 674
Additive Value of Pyridostigmine to Silodosin in the Management of Acute Urinary Retention Secondary to Benign Prostatic Hyperplasia: A Randomized Controlled Trial
Background: In men with progressive benign prostatic hyperplasia (BPH), acute urine retention (AUR) stands out as one of the most severe outcomes associated with aging. AUR is characterized by a sudden, painful inability to urinate. This research investigates the potential benefits of adding pyridostigmine to silodosin in the management of acute urinary retention secondary to benign prostatic hyperplasia. Methods: Patients aged 50 and above experiencing their first episode of AUR due to BPH, with a retention volume below 1000 milliliters, were enrolled in this study. A total of 140 patients were randomized into two groups: Group A received a daily dose of pyridostigmine bromide (60 mg tablet) alongside an 8 mg silodosin capsule, while Group B received a daily dose of silodosin (8 mg capsule) only. Trial registration number: NCT06319469 13 March 2024. Results: Among the 140 patients, 58 (82.9%) in Group A successfully underwent a trial without catheter (TWOC), compared to 47 (67.1%) in Group B. Group A exhibited significant improvements in international prostatic symptom score (IPSS) and uroflowmetry (UFR) at both 2 weeks and 3 months, with p-values of 0.001 and 0.003, respectively. Regarding postvoid residual volume (PVR), both groups were initially matched at baseline, showing significant continuous improvement at the second week and third month. Conclusions: The combination of pyridostigmine bromide (60 mg tablet) with silodosin proved to be more effective than silodosin alone in managing acute urinary retention caused by BPH. This was particularly true for patients who were suspected to have detrusor underactivity in addition to BPH.
- 21 January 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (3) , 674
Open AccessAdditive Value of Pyridostigmine to Silodosin in the Management of Acute Urinary Retention Secondary to Benign Prostatic Hyperplasia: A Randomized Controlled Trial
Background: In men with progressive benign prostatic hyperplasia (BPH), acute urine retention (AUR) stands out as one of the most severe outcomes associated with aging. AUR is characterized by a sudden, painful inability to urinate. This research investigates the potential benefits of adding pyridostigmine to silodosin in the management of acute urinary retention secondary to benign prostatic hyperplasia. Methods: Patients aged 50 and above experiencing their first episode of AUR due to BPH, with a retention volume below 1000 milliliters, were enrolled in this study. A total of 140 patients were randomized into two groups: Group A received a daily dose of pyridostigmine bromide (60 mg tablet) alongside an 8 mg silodosin capsule, while Group B received a daily dose of silodosin (8 mg capsule) only. Trial registration number: NCT06319469 13 March 2024. Results: Among the 140 patients, 58 (82.9%) in Group A successfully underwent a trial without catheter (TWOC), compared to 47 (67.1%) in Group B. Group A exhibited significant improvements in international prostatic symptom score (IPSS) and uroflowmetry (UFR) at both 2 weeks and 3 months, with p-values of 0.001 and 0.003, respectively. Regarding postvoid residual volume (PVR), both groups were initially matched at baseline, showing significant continuous improvement at the second week and third month. Conclusions: The combination of pyridostigmine bromide (60 mg tablet) with silodosin proved to be more effective than silodosin alone in managing acute urinary retention caused by BPH. This was particularly true for patients who were suspected to have detrusor underactivity in addition to BPH.
- Open Access
- 7 February 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (3) , 1106
STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy
The JAK-STAT signalling pathway regulates cellular processes like cell division, cell death and immune regulation. Dysregulation has been identified in solid tumours and STAT3 activation is a marker for poor outcome. The aim of this study was to explore potential therapeutic strategies by targeting this pathway in bladder cancer (BC). High STAT3 expression was detected in 51.3% from 149 patient specimens with invasive bladder cancer by immunohistochemistry. Protein expression of JAK, STAT and downstream targets were confirmed in 10 cell lines. Effects of the JAK inhibitors Ruxolitinib and BSK-805, and STAT3/5 inhibitors Stattic, Nifuroxazide and SH-4-54 were analysed by cell viability assays, immunoblotting, apoptosis and cell cycle progression. Treatment with STAT3/5 but not JAK1/2 inhibitors reduced survival, levels of phosphorylated STAT3 and Cyclin-D1 and increased apoptosis. Tumour xenografts, using the chicken chorioallantoic membrane (CAM) model responded to Stattic monotherapy. Combination of Stattic with Cisplatin, Docetaxel, Gemcitabine, Paclitaxel and CDK4/6 inhibitors showed additive effects. The combination of Stattic with the oncolytic adenovirus XVir-N-31 increased viral replication and cell lysis. Our results provide evidence that inhibitors against STAT3/5 are promising as novel mono- and combination therapy in bladder cancer.
- 7 February 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (3) , 1106
Open AccessSTAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy
The JAK-STAT signalling pathway regulates cellular processes like cell division, cell death and immune regulation. Dysregulation has been identified in solid tumours and STAT3 activation is a marker for poor outcome. The aim of this study was to explore potential therapeutic strategies by targeting this pathway in bladder cancer (BC). High STAT3 expression was detected in 51.3% from 149 patient specimens with invasive bladder cancer by immunohistochemistry. Protein expression of JAK, STAT and downstream targets were confirmed in 10 cell lines. Effects of the JAK inhibitors Ruxolitinib and BSK-805, and STAT3/5 inhibitors Stattic, Nifuroxazide and SH-4-54 were analysed by cell viability assays, immunoblotting, apoptosis and cell cycle progression. Treatment with STAT3/5 but not JAK1/2 inhibitors reduced survival, levels of phosphorylated STAT3 and Cyclin-D1 and increased apoptosis. Tumour xenografts, using the chicken chorioallantoic membrane (CAM) model responded to Stattic monotherapy. Combination of Stattic with Cisplatin, Docetaxel, Gemcitabine, Paclitaxel and CDK4/6 inhibitors showed additive effects. The combination of Stattic with the oncolytic adenovirus XVir-N-31 increased viral replication and cell lysis. Our results provide evidence that inhibitors against STAT3/5 are promising as novel mono- and combination therapy in bladder cancer.